Novadaq is pleased to invite all interested parties to participate in a conference call on August 12th, at 10:00 a.m. Eastern Time during which the results will be discussed.

Those wishing to access the live conference call by telephone should dial 1-877-407-8033 (within Canada and the United States) or 1-201-689-8033 (international callers) several minutes prior to the beginning of the call. A telephonic replay of the conference call will be made available until midnight on 9/12/10 and can be accessed by dialing 1-877-660-6853 (within Canada and the United States) or 1-201-612-7415 (international callers) and entering the account number 286 and the conference identification number 354599 when prompted.

The call will be archived for 365 days on the company's website at http://www.novadaq.com under the "Events" tab in the Investors section. In addition, a replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on Novadaq's website.

About Novadaq Technologies Inc.

Novadaq develops and markets real-time fluorescence imaging systems for the operating room. The company's core product, the SPY imaging system, is installed in approximately 100 hospitals in the United States. According to over 40 published journal articles, surgeons use SPY imaging for guidance during complex procedures to visualize vascular blockages; assess tissue perfusion; identify cancerous tumors and delineate margins; and visualize relevant lymph nodes for removal. Studies have shown conclusively that use of SPY imaging in plastic reconstruction, gastrointestinal and cardiac surgery procedures improves clinical outcomes and reduces costs of complications, demonstrating significant patient and economic value. Novadaq has an alliance with Intuitive Surgical in late stage development to incorporate SPY imaging into the da Vinci robotic system. Novadaq's minimally invasive imaging system is also in clinical development stage.

Forward-Looking Statements

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Novadaq in its public securities filings actual events may differ materially from current expectations. Novadaq disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.